Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Status of therapies in development for the treatment of age-related macular degeneration.

Hunt DW, Margaron P.

IDrugs. 2003 May;6(5):464-9. Review.

PMID:
12789601
[PubMed - indexed for MEDLINE]
2.

[The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists--comments on the current therapy for neovascular AMD].

Pauleikhoff D, Bornfeld N, Gabel VP, Holz F, Roider H; German Ophthalmological Society; Retinological Society; Professional Association of Ophthalmologists.

Klin Monbl Augenheilkd. 2005 May;222(5):381-8. Review. German.

PMID:
15912454
[PubMed - indexed for MEDLINE]
3.

Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.

Kaiser PK.

Curr Med Res Opin. 2007 Mar;23(3):477-87. Review.

PMID:
17355729
[PubMed - indexed for MEDLINE]
4.

Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.

Verteporfin Roundtable Participants.

Retina. 2005 Feb-Mar;25(2):119-34. Review.

PMID:
15689800
[PubMed - indexed for MEDLINE]
5.

Photodynamic therapy with verteporfin for choroidal neovascularization due to age-related macular degeneration and other causes: a New Zealand outcomes study.

Sharp DM, Lai S, Markey CM.

Clin Experiment Ophthalmol. 2007 Jan-Feb;35(1):24-31.

PMID:
17300567
[PubMed - indexed for MEDLINE]
6.

Emerging drugs for age-related macular degeneration.

Augustin AJ, Offermann I.

Expert Opin Emerg Drugs. 2006 Nov;11(4):725-40. Review.

PMID:
17064228
[PubMed - indexed for MEDLINE]
7.

Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties.

Cruess AF, Zlateva G, Pleil AM, Wirostko B.

Acta Ophthalmol. 2009 Mar;87(2):118-32. doi: 10.1111/j.1755-3768.2008.01218.x. Epub 2008 Jun 13. Review.

PMID:
18577193
[PubMed - indexed for MEDLINE]
8.

Current treatment of age-related macular degeneration.

Zarbin M, Szirth B.

Optom Vis Sci. 2007 Jul;84(7):559-72. Review.

PMID:
17632299
[PubMed - indexed for MEDLINE]
9.

Cost effectiveness of treatments for wet age-related macular degeneration.

Mitchell P, Annemans L, White R, Gallagher M, Thomas S.

Pharmacoeconomics. 2011 Feb;29(2):107-31. doi: 10.2165/11585520-000000000-00000. Review.

PMID:
21244102
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

Earnshaw SR, Moride Y, Rochon S.

Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.

PMID:
18035208
[PubMed - indexed for MEDLINE]
11.

[Therapy of the wet form of age-related macular disease: the present state and perspectives].

Figurska M, Stankiewicz A.

Klin Oczna. 2005;107(4-6):334-9. Review. Polish.

PMID:
16118952
[PubMed - indexed for MEDLINE]
12.

[Age related macular degeneration: a review of anti-angiogenic treatments].

Razavi S, Coscas G, Soubrane G.

J Fr Ophtalmol. 2002 Sep;25(7):747-52. Review. French.

PMID:
12399735
[PubMed - indexed for MEDLINE]
Free Article
13.

Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration.

Parmeggiani F, Costagliola C, Gemmati D, D'Angelo S, Perri P, Scapoli GL, Catozzi L, Federici F, Sebastiani A, Incorvaia C.

Pharmacogenet Genomics. 2007 Dec;17(12):1039-46.

PMID:
18004208
[PubMed - indexed for MEDLINE]
14.

Neovascular age-related macular degeneration: potential therapies.

Chappelow AV, Kaiser PK.

Drugs. 2008;68(8):1029-36. Review.

PMID:
18484796
[PubMed - indexed for MEDLINE]
15.

Anti-angiogenic therapy of exudative age-related macular degeneration: current progress and emerging concepts.

Noël A, Jost M, Lambert V, Lecomte J, Rakic JM.

Trends Mol Med. 2007 Aug;13(8):345-52. Epub 2007 Jul 17. Review.

PMID:
17644433
[PubMed - indexed for MEDLINE]
16.

Antiangiogenic approaches to age-related macular degeneration today.

Bressler NM.

Ophthalmology. 2009 Oct;116(10 Suppl):S15-23. doi: 10.1016/j.ophtha.2009.06.048. Review.

PMID:
19800535
[PubMed - indexed for MEDLINE]
17.

Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.

Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J; Vision Health Cost-Effectiveness Study Group.

Arch Ophthalmol. 2009 Apr;127(4):533-40. doi: 10.1001/archophthalmol.2009.58.

PMID:
19365036
[PubMed - indexed for MEDLINE]
18.

Wet age-related macular degeneration.

Kulkarni AD, Kuppermann BD.

Adv Drug Deliv Rev. 2005 Dec 13;57(14):1994-2009. Epub 2005 Nov 23. Review.

PMID:
16309781
[PubMed - indexed for MEDLINE]
19.
20.

Treatment of neovascular age-related macular degeneration: past, present and future directions.

Smith BT, Joseph DP, Grand MG.

Curr Opin Ophthalmol. 2007 May;18(3):240-4. Review.

PMID:
17435433
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk